Aligos Therapeutics(US:ALGS) Globenewswireยท2025-08-06 20:05Core Viewpoint - Aligos Therapeutics, Inc. is advancing its clinical pipeline, particularly focusing on the Phase 2 B-SUPREME study of ALG-000184 for chronic HBV infection, while also reporting significant financial results for Q2 2025 [1][2][7]. Recent Business Progress - The Phase 2 B-SUPREME study of ALG-000184 has received regulatory approvals in multiple countries, including the US, China, and the UK, with site activations and subject screenings currently in progress [2][3]. - The study aims to evaluate the safety and efficacy of ALG-000184 compared to tenofovir disoproxil fumarate in approximately 200 untreated adult subjects with chronic HBV infection over 48 weeks [3]. - Phase 1 data presented at the EASL meeting indicates that ALG-000184 has the potential to replace standard care for chronic HBV suppression, with promising results showing 100% of subjects achieving HBV DNA < LLOQ after 96 weeks of treatment [2][3]. Pipeline Updates - ALG-055009 is being evaluated for metabolic dysfunction-associated steatohepatitis (MASH) and has shown statistically significant reductions in liver fat and improvements in atherogenic lipids after 12 weeks of treatment [5][12]. - ALG-097558, a pan-coronavirus protease inhibitor, is in a study assessing its efficacy in high-risk COVID-19 subjects, with funding expected from external sources [6][12]. Financial Results for Q2 2025 - Cash, cash equivalents, and investments totaled $122.9 million as of June 30, 2025, a significant increase from $56.9 million at the end of 2024, providing sufficient funding for operations into the second half of 2026 [7]. - The net loss for Q2 2025 was $15.9 million, or $(1.53) per share, compared to a net income of $5.1 million, or $0.81 per share, in Q2 2024 [8][18]. - Research and development expenses decreased to $14.0 million from $21.1 million in the same period of 2024, primarily due to reduced clinical study costs [9][18].